Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
Por:
Garde-Noguera J, Martin-Martorell P, De Julian M, Perez-Altozano J, Salvador-Coloma C, Garcia-Sanchez J, Insa-Molla A, Martin M, Mielgo-Rubio X, Marin-Liebana S, Blasco-Cordellat A, Blasco-Molla S, Girones R, Marquez-Medina D, Aparisi F, Cerda M, Macia-Escalante S, Sanchez A, Juan-Vidal O
Publicada:
1 ago 2018
Resumen:
Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need.
Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry.
A total of 175 patients were included. Median age was 61.5 years, 73.1% were men, 77.7% were ECOG-PS 0-1, and 86.7% were included with stage IV disease. Histology was non-squamous in 77.1%. Sixty-five received nivolumab in second line (37.1%). Thirty-eight patients had brain metastasis (22%), and 39 (22.3%) liver metastasis and 126 (72%) had more than one metastatic location. The ORR was 15.7% with median Progression free survival (PFS) 2.8 months and median OS 5.81 months. Stage III vs IV and time since the beginning of the previous line of treatment 6 vs < 6 months were associated with better response. PS 2, time since the previous line of treatment < 6 vs 6 months, and more than one metastatic location were independently associated with shorter OS in multivariable analysis (7.8 vs 2.7 months, 11.2 vs 4.6 months, and 9.4 vs 5.1 month). Finally, time since the previous treatment < 6 vs 6 months and more than one metastatic location were independently associated with shorter PFS in multivariable analysis (4.3 vs 2.3 months and 4.7 vs 2.3 months).
Poor PS, short period of time since the previous treatment, and more than one metastatic location were associated with poorer prognostic.
Filiaciones:
Garde-Noguera J:
Hosp Arnau Vilanova, C St Climent 12, Valencia 46015, Spain
Martin-Martorell P:
Univ Hosp Clin Valencia, Valencia, Spain
De Julian M:
Hosp Prov Castellon, Castellon de La Plana, Spain
Perez-Altozano J:
Hosp Gen Elche, Elche, Spain
Salvador-Coloma C:
Hosp Univ Politecn La Fe, Valencia, Spain
Garcia-Sanchez J:
Hosp Arnau Vilanova, C St Climent 12, Valencia 46015, Spain
Insa-Molla A:
Univ Hosp Clin Valencia, Valencia, Spain
Martin M:
Hosp Dr Peset, Valencia, Spain
Mielgo-Rubio X:
Hosp Univ Fdn Alcorcon, Alcorcon, Spain
Marin-Liebana S:
Hosp Manises, Manises, Spain
Blasco-Cordellat A:
Hosp Gen Univ Valencia, Valencia, Spain
Blasco-Molla S:
Hosp Sagunto, Sagunto, Spain
Girones R:
Hosp Lluis Alcanyis, Xativa, Spain
Marquez-Medina D:
Hosp Arnau Vilanova, Lleida, Spain
Aparisi F:
Hosp Virgen Lirios, Alcoy, Spain
Cerda M:
Univ Politecn Valencia, Valencia, Spain
Macia-Escalante S:
Pivotal CRO, Madrid, Spain
Sanchez A:
Hosp Prov Castellon, Castellon de La Plana, Spain
Juan-Vidal O:
Hosp Univ Politecn La Fe, Valencia, Spain
|